Immutep Raises A$10 Million Via Private Placement and Underwritten Entitlement Offer

Immutep获1000万澳元股权融资,计划推动免疫肿瘤和免疫疾病临床项目研究

2019-07-12 09:30:00 BioSpace

本文共613个字,阅读需2分钟

Immutep Limited , an Australian biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, has announced an equity financing to raise gross proceeds of approximately A$10 million comprising the following: (a) a private placement of 190.5 million new fully paid ordinary shares in the Company ("Shares") to multiple new and existing Australian and other institutional and professional investors at an issue price of A$0.021 per Share ("Offer Price") (representing a 16.7% discount to the volume weighted average price of the Company's ordinary shares as traded on the Australian Securities Exchange over the 5 days up to and including July 4, 2019) ("Private Placement"), raising a total of A$4 million before transaction-related expenses; and (b) a 1 for 11.8 fully underwritten pro rata non-renounceable entitlement offer of new Shares at the Offer Price to raise approximately A$6 million (“Entitlement Offer”). Only persons holding ordinary shares of the Company and having a registered address in Australia or New Zealand are entitled to participate in the Entitlement Offer. U.S. persons who own, directly or indirectly, ordinary shares or American Depositary Shares of the Company may not participate in the Entitlement Offer. These capital raising transactions are subject to customary closing conditions in Australia. Settlement of the Shares in the Private Placement is expected to occur on July 16, 2019 (Australian time) and in the Entitlement Offer in early August 2019. The Company will use the proceeds received from the Private Placement and the Entitlement Offer to finance its LAG-3 related clinical program in immuno-oncology and autoimmune disease. This includes the ongoing clinical development of eftilagimod alpha (“efti” or “IMP321”), via its TACTI-mel, TACTI-002, and INSIGHT clinical studies, development of IMP761 and for general corporate purposes.
Imutup Limited ,一家澳大利亚生物技术公司,开发新型免疫治疗癌症和自身免疫性疾病,宣布了一项股权融资,募集资金总额约1000万澳元,其中包括: ( a ) 以每股0.021澳元的发行价(「发售价」)向多名新投资者及现有澳洲及其他机构及专业投资者非公开配售190.5百万股本公司已缴足普通股(「股份」)(较本公司于截至七月四日(包括七月四日)止五天在澳洲证券交易所交易的普通股加权平均价格折让16.7%)2019年)(“私募”),在与交易相关的费用前总共募集400万澳元;以及 ( b ) a 为11.8按比例全额包销按发售价发售新股份之不可放弃权利要约,以筹集约6,000,000澳元(「权利要约」)。只有持有本公司普通股并在澳大利亚或新西兰有注册地址的人士才有权参与权利要约。直接或间接持有公司普通股或美国存托股份的美国人不得参与权利要约。 这些筹资交易须遵守澳大利亚的惯例成交条件。定向增发股份的交割预计于2019年7月16日(澳大利亚时间)和2019年8月初的《权利要约》中进行。 本公司将使用从私募和权利要约获得的收益,为其在免疫肿瘤和自身免疫性疾病领域的 LAG-3相关临床方案提供资金。这包括通过其 TACTI-mel 、 TACTI-002和 INSIGHT 临床研究进行的 eftilaimod alpha (简称“ efti ”或“ IM321”)的临床开发, IM761的开发和一般企业用途。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文